Army taps Vermillion for ovarian cancer Dx study

04/18/2013 | GenomeWeb Daily News (free registration)

The U.S. Army Medical Research and Materiel Command awarded Vermillion a contract to investigate the cost-benefits profile of the company's OVA1 test for ovarian cancer. The company will examine the assay's clinical use in managed care environments, and a multicenter clinical trial will evaluate the test as a presurgical standard of care in women who have pelvic masses.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care